Translate this page into:
Estrogen receptor and progesterone receptor status of breast cancer patients of eastern India: A multi-institutional study
*Corresponding author: Dr. Koushik Chatterjee. drkoushik.chatterjee@gmail.com
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Context: There is a paucity of any significant data on the estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer patients from the eastern part of India. Aims: This study aims to document the ER and PR status of breast cancer patients in the eastern Indian population, as catered by two premier tertiary care hospitals in Kolkata. Subjects and Methods: All breast cancer patients registered between January 1, 2013 and December 31, 2015, in the Departments of Oncology, of IPGMER and SSKM Hospitals and R. G. Kar Medical College and Hospital, Kolkata, who had at least undergone a core biopsy or surgery, were analyzed retrospectively for documentation of their ER and PR status, using the 2010 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) interpretation guidelines. Results: Over a period of 3 years, a total of 927 patients were included for the study. A total of 825 (89%) patients had their ER and PR data available for evaluation. ER and PR positive was seen in 312 (37.82%) patients, ER and PR negative in 399 (48.36%) patients, ER positive and PR negative in 71 (8.6%) patients, and ER negative and PR positive results was found in 43 (5.21%) patients. Conclusions: This is the first multi-institutional documentation of ER and PR status from eastern India, having a modest number of patients and one of the earliest documentations using the latest ASCO/CAP interpretation guidelines. These findings resemble the data from the south and also reiterate the fact that majority of the Indian breast cancer patients are still ER and PR negative in spite of the changes in the interpretation guidelines.
Keywords
References
- Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for Imunohistochemical testing of estrogen and progesterone receptors in breast cancer. JCO 2010;28:2784-95. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2040425. [Last cited on 2017 Mar 31].
- Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 1996;77:1465-71. Available from: https://www.ncbi.nlm.nih.gov/pubmed/8608530 [Last cited on 2017 Mar 31].
- Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF, et al. Hormone receptor status of breast cancer in India: A study of 798 tumours. Breast 2000;9:267-70. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1473217. [Last cited on 2017 Mar 31].
- Suvarchala SB, Nageswararao R. Carcinoma breast – Histopathological and hormone receptors correlation. J Biosci Tech2011;2:340-8. Available from: http://www.jbstonline.com/documents/vol2issue4/jbst2011020404.pd. [Last cited on 2017 Mar 31].
- Kaul R, Sharma J, Minhas SS, Mardi K. Hormone receptor status of breast cancer in the Himalayan region of Northern India. Indian J Surg 2011;73:9-12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077188. [Last cited on 2017 Mar 31].
- Dinshaw KA, Budrukkar AN, Chinoy RF, Sarin R, Badwe R, Hawaldar R, et al. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2005;63:1132-41. Available from: http://www.redjournal.org/article/S0360-3016 (05)00712-1/fulltex. [Last cited on 2017 Mar 31].